U.S., Feb. 27 -- ClinicalTrials.gov registry received information related to the study (NCT06848075) titled 'A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine' on Feb. 21.
Brief Summary: This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatment of moderate or severe migraine.
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Acute Migraine
Intervention:
DRUG: Elismetrep (K-304) Dose Level 1
Administered orally
DRUG: Elismetrep (K-304) Dose level 2
Administered orally
DRUG: Elismetrep (K-304) Dose level 3
Administered orally
DRUG: Elismetrep (K-304) Dose ...